Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Completed 4 Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 381 Breast Neoplasms 364 Colorectal Neoplasms 238 Stomach Neoplasms 218 Carcinoma, Hepatocellular 155 Lung Neoplasms 123 Neoplasms 120 Pancreatic Neoplasms 109 Prostatic Neoplasms 100 Neoplasm Metastasis 96 Recurrence 95 Rectal Neoplasms 95 Ovarian Neoplasms 90 Nasopharyngeal Carcinoma 88 Esophageal Neoplasms 82 Esophageal Squamous Cell Carcinoma 81 Lymphoma, Large B-Cell, Diffuse 79 Melanoma 75 Small Cell Lung Carcinoma 71 Uterine Cervical Neoplasms 70 Lymphoma 70 Leukemia, Myeloid, Acute 70 Brain Neoplasms 69 Sarcoma 68 Head and Neck Neoplasms 68 Squamous Cell Carcinoma of Head and Neck 67 Multiple Myeloma 65 Carcinoma, Renal Cell 63 Triple Negative Breast Neoplasms 61 Lymphoma, Non-Hodgkin 53

Interventions

Vorinostat 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unknown × Neuroectodermal Tumors × Clear all

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡